Higher Fatty Acid Or Salt Thereof Patents (Class 514/558)
-
Publication number: 20110054030Abstract: The present invention pertains to the use of essential fatty acids for the preparation of a food composition for treating in particular post-surgical pain and/or pain due to a post-surgical relapse in women having undergone an operation for endometriosis. Said essential fatty acids are preferably selected from the group consisting of long-chain polyunsaturated fatty acids of the omega-3 series, and in particular from the group comprising EPA and/or DHA.Type: ApplicationFiled: January 29, 2009Publication date: March 3, 2011Applicant: PHARMANUTRA S.R.L.Inventors: Felice Petraglia, Stefano Luisi, Andrea Lacorte, Germano Tarantino
-
Publication number: 20110054026Abstract: Antimicrobial compositions are provided comprising a pharmaceutically acceptable organic acid and a pharmaceutically acceptable surfactant. This synergistic combination allows compositions to be formulated at low concentrations that have efficacy in reducing bacterial counts by greater than 3 log within 5 minutes of contact while preserving the organoleptic properties of treated foods, including fresh produce. As shown in FIG. 1C the efficacy of six different compositions (A. 3% levulinic acid plus 2% SDS; B. 2% levulinic acid plus 1% SDS; C. 0.5% levulinic acid plus 0.05% SDS; D. 3% levulinic acid; E. 2% SDS and F. water) were tested for their ability to kill spores of Bacillus anthracis Sterne after 45 minutes of contact.Type: ApplicationFiled: May 21, 2009Publication date: March 3, 2011Inventors: Michael Patrick Doyle, Tong Zhao
-
Publication number: 20110054027Abstract: The present invention provides a method for the production of at least one fatty acid and/or oil from a plant cell suspension culture, the method comprising (i) maintaining a cell suspension culture of oil-producing plant cells under conditions such that the cultured cells synthesise and secrete at least one fatty acid and/or oil into the cell suspension culture medium; and (ii) extracting the thus secreted at least one fatty acid and/or oil from the cell suspension culture medium.Type: ApplicationFiled: April 28, 2009Publication date: March 3, 2011Applicant: NATURALLY SCIENTIFIC TECHNOLOGIES LIMITEDInventors: Peter Andrew Whitton, Geoffrey Robert Dixon, William Timothy Merrell
-
Patent number: 7897160Abstract: Stable emulsions comprising as a base one or more diene conjugated fatty acids. Amino acids and other macromolecules can be used to stabilize the emulsion. The emulsion is also useful as a carrier and delivery vehicle of the macromolecules to humans or animals in need of the macromolecules. Plant oil extracts, such as conjugated linoleic acid and its acylated derivatives, are useful as the diene conjugated fatty acids that form the base of the stable emulsion. The emulsions formed are useful as nutritional or cosmetic adjuvant for oral based nutrition, skin diseases, cosmetic utility, enhancing oral nutrition, or pharmacological benefit. Methods of producing and using the emulsions are also provided.Type: GrantFiled: June 2, 2006Date of Patent: March 1, 2011Inventor: David G. Changaris
-
Publication number: 20110046222Abstract: Provided are fatty acid amides of amino acids, uses thereof and pharmaceutical compositions including them.Type: ApplicationFiled: April 7, 2009Publication date: February 24, 2011Applicant: Yissum Research Development Company Of The Hebrew University Of Jerusalem, LTD.Inventors: Raphael Mechoulam, Itai Bab, Gary Milman, Reem Smoum
-
Publication number: 20110046221Abstract: Methods are provided for promoting longevity and decreasing the incidence of aging associated pathologies (e.g., cancer) by the administration of one or more of the following LFFA: linoleic, oleic and palmitic acid. Secondary LFFA derived from this set, as well as their CoA derivatives and synthetic analogs, are effective also in promoting longevity and delaying the onset of age associated disorders. In addition, interventions including LFFA and CoA LLFA formulations are described which protect the organism from acute physical stress, tissue damage and hypoxia (either due to trauma or secondary to surgical procedures.Type: ApplicationFiled: October 12, 2010Publication date: February 24, 2011Inventor: Marco CHACON
-
Publication number: 20110038953Abstract: The invention provides a method of treatment of a human or non-human subject to combat sub-dermal soft tissue pain therein, said method comprising administering to a subject in need thereof an effective amount of a physiologically tolerable strontium compound.Type: ApplicationFiled: October 27, 2010Publication date: February 17, 2011Inventors: Egil JELLUM, Bjørn Jarl Fagerlund, Clas Magne Kjølberg, Jo Klaveness
-
Publication number: 20110038943Abstract: Milkweed seed oil administered to an animal improves the health of the animal. This improvement is evidenced by the positive change in the analytical results of blood tests for cholesterol after the animal has been administered an effective amount of milkweed seed oil as compared to the blood test results of the animal before the milkweed seed oil was administered.Type: ApplicationFiled: August 11, 2010Publication date: February 17, 2011Applicant: Natural Fibers CorporationInventor: Herbert D. KNUDSEN
-
Patent number: 7888391Abstract: The present invention relates to the use of polyunsaturated fatty acids and one or more components which have a beneficial effect on total methionine metabolism selected from the group consisting of vitamin B12 and precursors thereof, vitamin B6 and derivatives thereof, folic acid, zinc and magnesium, in the manufacture of a preparation for improving the action of receptors. This preparation is advantageously applied in patients suffering from Parkinson's disease, Huntington's chorea, epilepsy, schizophrenia, paranoia, depression, sleep disorders, impaired memory function, psychoses, dementia and ADHD.Type: GrantFiled: March 10, 2008Date of Patent: February 15, 2011Assignee: N.V. NutriciaInventors: Amanda Johanne Kiliaan, Robert Johan Joseph Hageman
-
Patent number: 7884089Abstract: An antimicrobial coating composition consisting essentially of 70 to 80 wt. percent water; 5 to 10 wt. percent methyl alcohol; 3 to 8 wt. percent octadecyl dimethyl trimethoxy silylpropyl-ammonium chloride; 1 to 5 wt. percent chloropropyl trimethoxysilane; 0.5 to 1.5 wt. percent aminopropyltrialkoxysilane; 0.5 to 1.5 wt. percent of a surfactant; 1 to 1.5 wt. percent of an anti-microbial agent; and 0.5 to 2.5 wt. percent sulfuric acid.Type: GrantFiled: February 6, 2009Date of Patent: February 8, 2011Assignee: Xurex, Inc.Inventor: Bo H. Gimvang
-
Publication number: 20110028382Abstract: The invention provides compounds for use in a method of treating oral pharyngeal dysphagia in an individual and related products. One embodiment of the invention comprises administering to an individual an effective amount of a vanilloid receptor 1 (VR-1) agonist or high-affinity partial agonist to promote a swallow reflex.Type: ApplicationFiled: October 7, 2008Publication date: February 3, 2011Inventor: Kevin Burke Miller
-
Publication number: 20110028424Abstract: An oil-in-water microemulsion is provided, which includes, on the basis of its total weight, the following components of A) 55-95 wt % of a water phase; B) 0.1-20 wt % of an oil phase, wherein the oil phase comprises at least one oil/fat component containing polyoxypropylene chains; and C) 1-25 wt % of an oil-in-water nonionic emulsifier, wherein the emulsifier is selected from the following group of: hydrophilic nonionic surfactants with polyoxyethylene chains as hydrophilic groups, polyglycerol fatty acid esters, polyglycerol fatty alcohol ethers, sucrose fatty acid esters, and hydrocarbyl polyglycosides. The oil-in-water microemulsion carries a large amount of oil. In addition, the use of an oil/fat containing polyoxypropylene chains is disclosed for increasing the amount of oil carried in an oil-in-water microemulsion.Type: ApplicationFiled: July 27, 2010Publication date: February 3, 2011Applicant: EVONIK GOLDSCHMIDT GMBHInventors: Haizhou Zhang, Jiali Zou, Jingya Dai, Zhiheng Gao
-
Patent number: 7879905Abstract: Compositions containing 5,6,7-trihydroxyheptanoic acid and analogs and their use for treating posterior segment ocular diseases and diseases characterized by cellular hyperproliferation or angiogenesis, are disclosed.Type: GrantFiled: November 8, 2005Date of Patent: February 1, 2011Assignee: Alcon, Inc.Inventors: Peter G. Klimko, Mark R. Hellberg, David P. Bingaman, Daniel A. Gamache
-
Patent number: 7879908Abstract: The use of L-carnitine, or one of its pharmaceutically acceptable salts, is described in combination with glucose for the preparation of a medicament useful for diminishing the number of deaths caused by acute myocardial infarction, for reducing the number of days infarction patients spend in intensive care in hospital, and for reducing the number of episodes of post-infarction heart failure, in which the L-carnitine is administered intravenously within only a few hours of the onset of symptoms of acute myocardial infarction at an initial dose of 9 grams a day in combination with 1000-1500 mL of a 5% glucose solution for 5 days, after which the L-carnitine treatment is continued at a dose of 4 grams a day administered orally.Type: GrantFiled: June 21, 2005Date of Patent: February 1, 2011Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventor: Aleardo Koverech
-
Publication number: 20110020228Abstract: A method for the treatment of cancer involves delivering a surface active agent to an organism, where the surface active agent selectively partitions to and kills cancer cells as opposed to healthy cells. The surface active agent can be an ionic or a non-ionic surfactant with a HLB of less than 29 or a mixture of surface active agents with a HLB of less than 40, where the hydrophobic portion is a lesser fraction of the surface active agent than the hydrophilic portion. A fluorescence method of detecting and locating cancer cells in an organism involves delivering a surface active agent, where the surface active agent includes a fluorescence moiety that upon selective partitioning of the surface active agent to the cancer cells and irradiation by a radiation source to excite the fluorescence moiety, a fluorescence emission is observed permitting the detection and location of the cancerous tissue by local volumes of relatively high intensity emission.Type: ApplicationFiled: February 2, 2009Publication date: January 27, 2011Applicant: University of Florida Resarch Foundation, Inc.Inventors: Brij M. Moudgil, Manoj Varshney, Stephen R. Grobmyer
-
Patent number: 7875281Abstract: The present invention is a composition and method for repelling moles, voles, gophers, chipmunks and armadillos by applying a composition comprising castor oil, yellow grease and sodium lauryl sulfate to plant materials.Type: GrantFiled: February 4, 2008Date of Patent: January 25, 2011Assignee: Liquid Holding Co., Inc.Inventor: George J. Ferko, IV
-
Publication number: 20110009487Abstract: A method of obtaining a solid component rich in a petroselinic compound from the seed of a plant of the Apiaceae or Araliaceae families, the method comprising: (a) treating a portion of the seed of the plant with an extraction solvent; and (b) inducing formation of the solid component.Type: ApplicationFiled: December 22, 2008Publication date: January 13, 2011Applicant: BANGOR UNIVERSITYInventors: Mark Stephen Baird, David Preskett
-
Publication number: 20110003767Abstract: This invention relates to methods of using inhibitors of the enzyme acetyl-CoA carboxylase (ACC) for the treatment, prevention, inhibition or alleviation of diseases associated with neuronal hypometabolism and/or loss of cognitive function caused by reduced neuronal metabolism such as, for example, Age Associated Memory Impairment (AAMI), Mild Cognitive Impairment (MCI), Alzheimer's disease, Parkinson's disease, Friedreich's Ataxia (FRDA), GLUT1-deficient Epilepsy, Leprechaunism and Rabson-Mendenhall Syndrome, Coronary Arterial Bypass Graft (CABG) dementia, anesthesia induced memory loss, Huntington's disease and many others.Type: ApplicationFiled: May 14, 2008Publication date: January 6, 2011Applicant: NEUERA PHARMACEUTICALS, INC.Inventor: Samuel T. Henderson
-
Publication number: 20110003796Abstract: Method for the treatment of psychiatric disorders, comprising administering to a subject in need thereof an amount of fatty acids and a suboptimal dose of at least one antidepressant. Wherein the fatty acid may be omega-3 (?3), for example the docohexaenoic acid (DHA) and the eicosapentaenoic acid (EPA). The omega-3 fatty acid may be administered orally, in amounts that may be variable, for example in amounts between 0.15 and 1.00 g/kg/day. The antidepressant may be any antidepressant, preferably the antidepressant is fluoxetine or mirtazapine in sub-optimal doses.Type: ApplicationFiled: July 6, 2009Publication date: January 6, 2011Applicants: Consejo Nacional de Investigaciones Cientificas y Tecnicas (Conicet), Universidad Nacional de la RiojaInventors: Analia Gabriela REINES, Carlos Horacio LAINO
-
Publication number: 20100330004Abstract: The invention includes a method of increasing the substantivity of a personal care composition to hair, skin or nails by preparing a composition of an aqueous phase, a non-aqueous phase and a neutralized amino acid ester that is a reaction product of a neutral amino acid having a non-polar side chain with a long chain fatty alcohol and is represented by formula (I): wherein R1 is an alkyl group; R2 is a linear or branched carbon chain; and the amine group of the amino acid is neutralized with an acid. The composition is substantially free of petrochemicals and/or derivatives of petrochemical materials. The aqueous phase and the non-aqueous phase are emulsified by the neutralized amino acid ester. Other methods and an emulsifiers that is the neutralized amino acid ester are included. Because the neutralized amino acid ester and the compositions do not contain petrochemical-derived ingredient, the products are natural.Type: ApplicationFiled: June 29, 2010Publication date: December 30, 2010Applicant: Inolex Investment CorporationInventor: Rocco Burgo
-
Publication number: 20100331414Abstract: According to the present invention, crystals comprising (2R)-2-propyloctanoic acid and an amine, which can be used as bulk drugs for safely orally administrable solid preparations with keeping the pharmacological effect, are provided. Among these crystals, the crystal with dibenzylamine per se is particularly useful as bulk drug for pharmaceuticals and can be used as an intermediate to produce (2R)-2-propyloctanoic acid having an optical purity of more than 99.5% e.e. which has not been obtained.Type: ApplicationFiled: August 31, 2010Publication date: December 30, 2010Applicant: ONO PHARMACEUTICAL CO., LTDInventors: Tomoyuki HASEGAWA, Yasufumi Kawanaka, Eiji Kasamatsu
-
Patent number: 7858662Abstract: The invention relates to a medicament containing a compound of general formula (1), where R1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkynyl group, preferably a C11-C15 alkyl, alkylene or alkynyl group, particularly a C11-C13 alkyl, alkylene or alkynyl group, most preferably a C13 alkyl group, R2=independently, a straight or branched C1-C8 alkyl, alkylene or alkynyl group, preferably a C1-C6 alkyl, alkylene or alkynyl group, in particular a C2-C4 alkyl, alkylene or alkynyl group, most preferably a C3 alkyl group, a —[CH2—(CH2)m—O]nH group with n=1 to 10, preferably n=1 to 5, m=1 to 5, preferably m=1 to 3, a —CH2—[CH—(OH)]p[CH2—(R3)]— group, where R3=independent H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tuType: GrantFiled: November 18, 2002Date of Patent: December 28, 2010Assignee: MediGene AGInventors: Yunik Chang, Robert Lathrop, Erwin Böhm, Irene Gander-Meisterernst, Regina Greger, Johanna Holldack, Ulrich Moebius
-
Publication number: 20100317734Abstract: An antimicrobial composition comprising a blend of two or more natural free fatty acids derivable from milk serum lipid, the free fatty acids being selected from: butyric (C4); caproic (C6); caprylic (C8); capric (C10); lauric (C12); myristic (C14); palmitic (C 16): palmitoleic 5 (C16:1); stearic (C1 8); oleic (C18:1); linoleic (Cl 8:2); linolenic (C18:3); and esterified derivatives thereof, and a milk, protein as an emulsifying agent for the free fatty acids wherein at least 35% of the total lipid content comprises free fatty acids selected from one or more of: butyric, caproic, caprylic, capric and lauric.Type: ApplicationFiled: December 4, 2008Publication date: December 16, 2010Inventors: Michael Anthony Folan, Colm O'Brien, Colum Dunne
-
Patent number: 7851642Abstract: Disclosed are ?-amino-?-hydroxy-?-aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.Type: GrantFiled: June 12, 2009Date of Patent: December 14, 2010Assignee: Novartis AGInventors: Daniel Kaspar Baeschlin, Juergen Klaus Maibaum, Holger Sellner
-
Patent number: 7851507Abstract: Use of hydroxyoleic acid and its analogous compounds in the manufacture of drugs. Describes the use of hydroxyoleic acid and its analogs of general formula I: COOH—CHR—(CH2)m—CH?CH—(CH2)n—CH3, in which m and n have, independently, a value of 0-15 and R can be any residue with molecular weight below 200 Da, in the manufacture of drugs that can be used in the treatment of cancer, hypertension, obesity or diseases mediated by alteration of the membrane structure and the consequent regulation of G-proteins or of the receptors coupled to them.Type: GrantFiled: April 15, 2008Date of Patent: December 14, 2010Assignee: Universitat des Less Illes BalearsInventor: Pablo Vicente Escriba-Ruiz
-
Publication number: 20100310613Abstract: A drug delivery system for the controlled release of a pharmaceutically-active compound by oral route comprises an intercalate of a layered double hydroxide having, before intercalation, layers of metal hydroxides, and having intercalated therein a pharmaceutically-active compound having at least one anionic group. A preferred layered double hydroxide is one that has layers which comprise [LiAl2(OH)6]+. The drug delivery system has use in the delivery of drugs such as 4-biphenylacetic acid, Diclofenac, Gemfibrozil, Ibuprofen, Naproxen, 2-Propylpentanoic acid and Tolfenamic acid.Type: ApplicationFiled: June 23, 2010Publication date: December 9, 2010Inventor: Dermot Michael O'Hare
-
Publication number: 20100298433Abstract: The present invention is directed to a method of preventing or treating a gastrointestinal condition in a subject, that includes administering one or more branched chain fatty acid to the subject under conditions effective to prevent 5 or treat the gastrointestinal condition in the subject. The present invention is also directed to methods of promoting gastrointestinal health in a subject and propagation of probiotic organisms. Also disclosed is a formulation which includes one or more branched chain fatty acid and an aqueous phase emulsified with the one or more branched chain fatty acids, where the formulation includes 10 over 25 wt % of the one or more branched chain fatty acid.Type: ApplicationFiled: September 16, 2008Publication date: November 25, 2010Applicant: CORNELL UNIVERSTIYInventors: James Thomas Brenna, Rinat Ran-Ressler
-
Publication number: 20100298268Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.Type: ApplicationFiled: December 26, 2008Publication date: November 25, 2010Inventors: Ann Hsu, Jim H. Kou, Laman Alani
-
Publication number: 20100297040Abstract: In recent years the demand for cosmetic compositions and cosmetic methods for improving the appearance and condition of skin has grown enormously; consumers are seeking topical skin care products that help treat or delay the signs of natural (chronoaging) and environmental aging. The present invention relates to topical compositions for application to human skin and to their use in improving the condition and appearance of skin. It is based on the premise that effective treatment of normal skin conditions due to natural or environmental aging, such as wrinkles, lines, sagging, hyperpigmentation and age spots, and/or of sensitive, dry, rough, flaky, red, itchy, irritated skin may be obtained through the application of cosmetic compositions to the skin which comprise a combination of collagen stimulators, phytoestrogens, plant derived anti-inflammatory agents, fatty acid, antioxidants.Type: ApplicationFiled: April 2, 2010Publication date: November 25, 2010Inventor: Candace Rose Keefe
-
Patent number: 7834058Abstract: A method of treating hyperinsulinemia. The method includes administering a therapeutically effective amount of a compound selected from the group consisting of catalpic acid, glyceride esters thereof, pharmaceutically-suitable salts thereof, and combinations thereof. The compound may be administered orally or parenterally.Type: GrantFiled: July 3, 2008Date of Patent: November 16, 2010Assignee: Nutrition Therapeutics, Inc.Inventor: Josep Bassaganya-Riera
-
Publication number: 20100286269Abstract: Use of medium-chain length fatty acids such as capric acid, caprylic acid or lauric acid and their salts or mono- or di- or triglycerides as nephroprotection agents to protect against renal failure progression in chronic kidney diseases This includes the treatment of kidney diseases associated with nephrectomy, renal fibrosis, glomerular scelrosis and end-stage renal disease Also includes the protection of the kidney against cytotoxic agent used in chemotherapy or autoimmune diseases or transplantation Further includes the treatment of renal failure progression associated with hypertension, infarct, tumour, diabetes mellitus, autoimmunity or inflammation.Type: ApplicationFiled: November 3, 2008Publication date: November 11, 2010Applicant: Prometic Biosciences Inc.Inventors: Vincent Pichette, Francois Leblond, Mouna Lagraoui, Lyne Gagnon
-
Publication number: 20100286589Abstract: A method and chemical composition for modifying and dissolving atherosclerotic plaques formed in blood vessels of a patient is provided. The chemical composition comprising one or more of an organic substance, an inorganic substance, and a bioactive product is administered at sites of the plaques formed in the patient's blood vessels. The chemical composition comprises, for example, one or more of d-limonene, propylene glycol, octanic acid, 2-octane, and glycerine. The chemical composition enables modification of the plaques by altering composition of the plaques. The modification comprises partial dissolution, complete dissolution or elimination of the plaques. The modification makes the plaques amenable to different forms of plaque treatment, for example, balloon angioplasty, stenting, atherectomy, etc. The modified plaques are eliminated from the body of the patient.Type: ApplicationFiled: May 4, 2010Publication date: November 11, 2010Inventor: Kusai Saadeldin Aziz
-
Publication number: 20100286270Abstract: Germicidal compositions containing one or more N,N-bis(3-aminopropyl) C6-C18 alkyl amines, such as N,N-bis(3-aminopropyl)dodecylamine, and methods of using the compositions for treatment or prevention of infectious hoof diseases are disclosed. The germicidal compositions remain active in the presence of manure, which eliminates the need to pre-clean the hooves before use, and have particular utility for treating or preventing papillomatous digital dermatitis, interdigital phlegmon, interdigital dermatitis, laminitis, white line disease, heel erosion and other hoof diseases.Type: ApplicationFiled: September 10, 2007Publication date: November 11, 2010Applicant: DELAVAL HOLDINGS ABInventors: Chris Foret, Alex Skender, Thomas C. Hemling
-
Publication number: 20100278759Abstract: The present invention relates to an oil-in-water emulsion topical delivery system comprising an oil phase; an aqueous phase; phenoxyethanol; an effective exfoliatingamount of a hydrophobic hydroxycarboxylic acid; a non-ionic emulsifier having an HLB of from about 7 to about 10; and at least one skin-supporting ordermatopharmaceutically active agent.Type: ApplicationFiled: February 8, 2007Publication date: November 4, 2010Inventor: Howard Murad
-
Publication number: 20100272663Abstract: The present invention relates to a cosmetic composition including, in a physiologically acceptable medium: (a) at least 30% by weight of an anhydrous gel having a viscosity of at least 180 000 cP-s at 25° C. which includes at least one oil and at least one copolymer of styrene and at least one olefin other than styrene; (b) at least one specific glycerol diester; and (c) optionally at most 10% by weight of wax(es), the composition exhibiting a phase shift ? between its elastic modulus (G?) and its viscous modulus (G?) of less than 45° at a frequency of 30 to 50 Hz. It also relates to a cosmetic method for caring for or making up the lips, including the topical application to the lips of the abovementioned composition.Type: ApplicationFiled: December 10, 2008Publication date: October 28, 2010Applicant: CHANEL PARFUMS BEAUTEInventors: Stephanie Pierre, Michele Mousset, Celine Carles
-
Publication number: 20100273881Abstract: The present invention provides a use of a lipid composition for the preparation of a nutritional, pharmaceutical or nutraceutical composition or a functional food, for the prevention and treatment of gastrointestinal diseases and disorders, and for promoting intestinal development, maturation, adaptation and differentiation.Type: ApplicationFiled: October 2, 2008Publication date: October 28, 2010Inventors: Fabiana Bar Yosef, Gai Ben Dror, Tzafra Cohen, Yael Lifshitz
-
Publication number: 20100267643Abstract: Provided herein are compositions and methods for treating diabetes, obesity, and other metabolic diseases, disorders or conditions with chemosensory receptor ligands. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.Type: ApplicationFiled: April 20, 2010Publication date: October 21, 2010Applicant: ELCELYX THERAPEUTICS, INC.Inventors: Alain BARON, Martin R. BROWN, Christopher R.G. JONES
-
Publication number: 20100266522Abstract: The present invention discloses petrolatum based composition containing silicone oils which are structured with specific blend and ratio of fatty acids.Type: ApplicationFiled: April 15, 2009Publication date: October 21, 2010Applicant: Conopco, Inc., d/b/a UNILEVERInventors: Tamara Litvin, Joseph Oreste Carnali, Qiu Qiang, Alexander Lips
-
Patent number: 7812199Abstract: The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.Type: GrantFiled: February 28, 2007Date of Patent: October 12, 2010Assignee: Esperion Therapeutics, Inc.Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
-
Patent number: 7812056Abstract: A fine particle dispersant containing at least one member selected from the group consisting of ester compounds of the following general formula (I) of ditrimethylolpropane and a fatty acid(s), polycondensates of ditrimethylolpropane and a polyvalent carboxylic acid(s), polycondensates of the ester compound of the following general formula (I) and the polyvalent carboxylic acid(s), polycondensates of an ester compound of ditrimethylolpropane and the polyvalent carboxylic acid(s) and the fatty acid(s), and polycondensates of ditrimethylolpropane, the fatty acid(s) and the polyvalent carboxylic acid(s). wherein R1 to R4 each independently represent a hydrogen atom or a fatty acid residue, with the proviso that at least one of them is a hydrogen atom. This fine particle dispersant is excellent in fine particle dispersibility and the properties (smell and color) thereof are scarcely deteriorated in heat stability tests.Type: GrantFiled: September 28, 2004Date of Patent: October 12, 2010Assignee: The Nisshi OilliO Group, Ltd.Inventors: Naoki Gotou, Taro Ehara, Hisanori Kachi, Yoshiaki Iwamoto
-
Publication number: 20100247564Abstract: The methods, kits, articles, and compositions of the invention feature a natural product (e.g., Sargassum fusiforme), an extract thereof, and fatty acid components of the extract (e.g., palmitic acid) for the treatment of a viral infection, e.g., HIV or herpes. The natural products used in the methods and compositions of the invention include brown algae, specifically algae of the Sargassum fusiforme species. The Sargassum fusiforme algae, extracts thereof, specific components of the extract, and related compounds of the invention may be used to treat or prevent HIV and herpes infections.Type: ApplicationFiled: May 23, 2008Publication date: September 30, 2010Inventors: David Yue-wei Lee, Mario Canki
-
Publication number: 20100249747Abstract: Compositions and methods of employing compositions in flushing and coating medical devices are disclosed. The compositions include combinations of a chelating agent, anticoagulant, or antithrombotic agent, with a C4-C9 carboxylate antimicrobial agent, such as octanoic acid. Methods of using these compositions for coating a medical device and for inhibiting catheter infection are also disclosed. Particular combinations of the claimed combinations include, for example, octanoic acid or other C4-C9 carboxylate antimicrobial agent together with EDTA, EGTA, DTPA, heparin and/or hirudin in a pharmaceutically acceptable diluent.Type: ApplicationFiled: March 26, 2009Publication date: September 30, 2010Applicant: Organic Medical Ventures, L.L.C.Inventors: Stanley L. Mills, Jacqueline L. Mills, Robert D. Maurer, Gary L. Rayburn, Marvin A. Cuchens
-
Publication number: 20100240753Abstract: The present invention is directed to an improved effectiveness pharmaceutical carrier comprising anyone or a combination of edible or pharmaceutical acceptable fatty acids and anyone or a combination of non-ionic surfactants, which is capable of improving the bio-absorption of drugs with intermediate log P ranging from 2 to 4 (having poor solubility in both water and triglycerides) as well as those with high log P of more than 4.Type: ApplicationFiled: June 15, 2007Publication date: September 23, 2010Inventors: Bee Hong Ng, Wai Peng Choy, Jia Woei Wong, June Lay Choo Khoo, David Sue San Ho, Kah Hay Yuen
-
Publication number: 20100240683Abstract: The present invention relates to a combination therapy for the treatment of cardiovascular disorders. More particularly, the invention relates to compositions combining long-chain optionally substituted amphipatic carboxylates (known as MEDICA drugs) and particularly, M16??, M16?? and M18??, with HMG-CoA reductase inhibitors (known as statins). The compositions of the invention may particularly be used for the treatment of cardiovascular disorders, for elevating HDL-cholesterol levels, decreasing non-HDL-cholesterol and particularly triglycerides, and decreasing insulin resistance in a subject suffering from Metabolic Syndrome or cardiovascular disorders. The invention further provides methods of treatment of such disorders using these combined compositions.Type: ApplicationFiled: February 26, 2008Publication date: September 23, 2010Applicant: Syndromex Ltd.Inventor: Jacob Bar-Tana
-
Publication number: 20100233232Abstract: The present invention is directed toward fatty acid-based particles, and methods of making such particles. The particles can be associated with an additional, therapeutic agent. Also provided herein is a method of forming fatty acid particles, comprising associating a cross-linked, fatty acid-derived biomaterial with a cryogenic liquid; and fragmenting the bio material/cryogenic liquid composition, such that fatty acid particles are formed. The particles can be used for a variety of therapeutic applications.Type: ApplicationFiled: March 10, 2009Publication date: September 16, 2010Inventors: Thomas M. SWANICK, Joseph FERRARO, Lisa ROGERS, Paul MARTAKOS
-
Publication number: 20100234460Abstract: Germicidal compositions containing at least one carboxylic acid combined with at least one nonionic or anionic surfactant, and methods of using the compositions for treatment or prevention of infectious hoof diseases are disclosed. The germicidal compositions remain active in the presence of manure, which eliminates the need to pre-clean the hooves before use. The compositions have particular utility for treating or preventing papillomatous digital dermatitis, interdigital phlegmon, interdigital dermatitis, laminitis, white line disease, heel erosion and other hoof diseases.Type: ApplicationFiled: September 10, 2007Publication date: September 16, 2010Applicant: DELAVAL HOLDINGS ABInventors: Chris Foret, Alex Skender, Thomas C. Hemling, Fahim U. Ahmed, Camelia N. Traistaru
-
Patent number: 7795302Abstract: Rosacea is treated with a composition comprising an antimicrobial and at least one of an anti-inflammatory and a non-retinoid inhibitor of at least one of NF-KB, AP-1, MMPs, adhesion molecules, TLRs, and CD14. The composition may further comprise a retinoid.Type: GrantFiled: November 30, 2005Date of Patent: September 14, 2010Assignee: The Regents of the University of MichiganInventors: Sewon Kang, John J. Voorhees, Gary J. Fisher
-
Publication number: 20100227924Abstract: The invention relates to a method for producing eicosapentanoic acid, docosapentanoic acid and/or docohexanoic acid in transgenic plants. According to said method, the plant is provided with at least one nucleic acid sequence coding for a polypeptide with a ?6 desaturase activity, at least one nucleic acid sequence coding for a polypeptide with a ?6 elongase activity, at least one nucleic acid sequence coding for a polypeptide with a ?5 desaturase activity, and at least one nucleic acid sequence coding for a polypeptide with a ?5 elongase activity, the nucleic acid sequence coding for a polypeptide with a ?5 elongase activity being modified in relation to the nucleic acid sequence in the organism from which the sequence originates, such that it is adapted to the codon use in at least one type of plant. For the production of docosahexanoic acid, at least one nucleic acid sequence coding for a polypeptide with a ?4 desaturase activity is also introduced into the plant.Type: ApplicationFiled: February 21, 2007Publication date: September 9, 2010Applicant: BASF Plant Science GmbHInventors: Petra Cirpus, Jörg Bauer, Xiao Qiu, Guohai Wu, Bifang Cheng, Martin Truksa, Tom Wetjen
-
Publication number: 20100222428Abstract: A seven-carbon fatty acid or derivative thereof has been identified as an excellent energy source for humans or human infants. A nutritional supplement suitable for humans or human infants comprising a seven carbon fatty acid chain compound or derivative thereof can be used to increase energy production derived from fatty acid metabolism. For example, administering a seven carbon fatty acid chain compound or derivative thereof can be used to accelerate the growth rate of a prematurely born human infant.Type: ApplicationFiled: March 8, 2010Publication date: September 2, 2010Applicant: BAYLOR RESEARCH INSTITUTEInventor: Charles R. Roe
-
Publication number: 20100215816Abstract: An antimicrobial composition for food applications includes a chelating agent and a lauric acid derivative. The antimicrobial composition optionally includes one or more carboxylic acid derivatives. The chelating agent, the lauric acid derivative, and if present, one or more carboxylic acid derivatives are collectively present in an amount that is less that a taste threshold.Type: ApplicationFiled: March 28, 2008Publication date: August 26, 2010Inventors: Zuoxing Zheng, Charles Arthur Kennett, Karl Ragnarsson, Jeffrey Semanchek